<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/89BD5E8F-7B26-4C2F-A710-9970A0D54778/chart/price-vs-fair-value?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/89BD5E8F-7B26-4C2F-A710-9970A0D54778/chart/price-vs-fair-value"/></p>
<p>納斯達克：BRKR 1 年股價與公允價值</p>
<p>探索來自社區的 Bruker 公允價值並選擇您的觀點</p>
<p><strong>Bruker Corporation</strong>（納斯達克：BRKR）的股價在過去一個月表現非常糟糕，下降了 31%。最近的下跌使得股東在過去一年中遭遇了 51% 的損失，真是災難性的結果。</p>
<p>儘管其股價大幅下跌，但考慮到美國生命科學行業幾乎一半的公司市銷率（&#34;P/S&#34;）超過 3.5 倍，甚至超過 6 倍的市銷率也並不罕見，Bruker 目前可能仍然看起來是一個強有力的買入機會，其市銷率為 1.3 倍。然而，市銷率可能較低是有原因的，需要進一步調查以確定是否合理。</p>
<p>特朗普承諾要&#34;釋放&#34;美國的石油和天然氣，這 15 只美國股票的發展有望受益。</p>
<p>查看我們對 Bruker 的最新分析</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/527317-ps-multiple-vs-industry-1-dark-2/1754836775472?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/527317-ps-multiple-vs-industry-1-dark-2/1754836775472"/></p>
<p>納斯達克：BRKR 市銷率與行業比較 2025 年 8 月 10 日</p>
<h3>Bruker 最近的表現如何？</h3>
<p>Bruker 最近確實表現不錯，因為其收入增長超過了大多數其他公司。可能許多人預計強勁的收入表現將大幅下降，這抑制了股價，因此市銷率也隨之下降。如果不是這樣，那麼現有股東對未來股價的方向有理由感到相當樂觀。</p>
<p>想知道分析師如何看待 Bruker 的未來與行業的比較嗎？那麼，我們的 <strong>免費</strong> 報告是一個很好的起點。</p>
<h2>收入增長指標告訴我們關於低市銷率的什麼？</h2>
<p>為了證明其市銷率的合理性，Bruker 需要實現顯著低於行業的微弱增長。</p>
<p>回顧過去，我們看到公司去年成功實現了 10% 的收入增長。令人欣慰的是，收入在三年前的基礎上總共增長了 39%，部分得益於過去 12 個月的增長。因此，股東們肯定會歡迎這些中期收入增長率。</p>
<p>展望未來，覆蓋該公司的 11 位分析師的估計顯示，未來三年收入預計將每年增長 3.2%。與此同時，行業的其他部分預計每年將增長 6.8%，這顯然更具吸引力。</p>
<p>根據這些信息，我們可以看到為什麼 Bruker 的市銷率低於行業。似乎大多數投資者預計未來增長有限，因此只願意為該股票支付較低的價格。</p>
<h2>Bruker 的市銷率對投資者意味着什麼？</h2>
<p>Bruker 的股價暴跌，其市銷率也隨之下降。雖然市銷率不應成為您是否購買股票的決定性因素，但它是收入預期的一個相當有效的晴雨表。</p>
<p>我們已經確定，Bruker 維持其低市銷率是因為其預測增長低於更廣泛的行業，正如預期的那樣。現在，股東們接受低市銷率，因為他們承認未來的收入可能不會帶來任何令人愉快的驚喜。除非這些條件改善，否則它們將繼續在這些水平上形成股價的障礙。</p>
<p>此外，您還應該瞭解我們發現的 <strong>Bruker 的 3 個警告信號</strong>（其中 1 個是無法忽視的）。</p>
<p>如果您對 Bruker 的業務實力 <strong>不確定</strong>，為什麼不探索我們互動的股票列表，尋找一些您可能錯過的具有良好商業基礎的其他公司呢？</p>

布魯克

<p>布魯克公司（NASDAQ:BRKR）的股價在過去一個月下跌了 31%，導致股東在過去一年中損失了 51%。儘管出現了這種下滑，其市銷率（P/S）為 1.3 倍，仍然表明與行業同行相比，可能仍然是一個買入機會。然而，分析師預測布魯克的收入增長將落後於行業，預計年增長率僅為 3.2%，而行業的年增長率為 6.8%。這種對未來增長有限的預期反映在低市銷率上，表明股價可能面臨潛在障礙</p>

<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/89BD5E8F-7B26-4C2F-A710-9970A0D54778/chart/price-vs-fair-value" alt="" original-src="https://images.simplywall.st/company/89BD5E8F-7B26-4C2F-A710-9970A0D54778/chart/price-vs-fair-value"/></p>
<p>NasdaqGS:BRKR 1 Year Share Price vs Fair Value</p>
<div class="lb-trans"><p>納斯達克：BRKR 1 年股價與公允價值</p>
</div><p>Explore Bruker's Fair Values from the Community and select yours</p>
<div class="lb-trans"><p>探索來自社區的 Bruker 公允價值並選擇您的觀點</p>
</div><p>The <strong>Bruker Corporation</strong> (NASDAQ:BRKR) share price has fared very poorly over the last month, falling by a substantial 31%. The recent drop completes a disastrous twelve months for shareholders, who are sitting on a 51% loss during that time.</p>
<div class="lb-trans"><p><strong>Bruker Corporation</strong>（納斯達克：BRKR）的股價在過去一個月表現非常糟糕，下降了 31%。最近的下跌使得股東在過去一年中遭遇了 51% 的損失，真是災難性的結果。</p>
</div><p>Although its price has dipped substantially, Bruker may still look like a strong buying opportunity at present with its price-to-sales (or &#34;P/S&#34;) ratio of 1.3x, considering almost half of all companies in the Life Sciences industry in the United States have P/S ratios greater than 3.5x and even P/S higher than 6x aren't out of the ordinary. However, the P/S might be quite low for a reason and it requires further investigation to determine if it's justified.</p>
<div class="lb-trans"><p>儘管其股價大幅下跌，但考慮到美國生命科學行業幾乎一半的公司市銷率（&#34;P/S&#34;）超過 3.5 倍，甚至超過 6 倍的市銷率也並不罕見，Bruker 目前可能仍然看起來是一個強有力的買入機會，其市銷率為 1.3 倍。然而，市銷率可能較低是有原因的，需要進一步調查以確定是否合理。</p>
</div><p>Trump has pledged to &#34;unleash&#34; American oil and gas and these 15 US stocks have developments that are poised to benefit.</p>
<div class="lb-trans"><p>特朗普承諾要&#34;釋放&#34;美國的石油和天然氣，這 15 只美國股票的發展有望受益。</p>
</div><p>View our latest analysis for Bruker</p>
<div class="lb-trans"><p>查看我們對 Bruker 的最新分析</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/527317-ps-multiple-vs-industry-1-dark-2/1754836775472" alt="" original-src="https://images.simplywall.st/asset/chart/527317-ps-multiple-vs-industry-1-dark-2/1754836775472"/></p>
<p>NasdaqGS:BRKR Price to Sales Ratio vs Industry August 10th 2025</p>
<div class="lb-trans"><p>納斯達克：BRKR 市銷率與行業比較 2025 年 8 月 10 日</p>
</div><h3>How Has Bruker Performed Recently?</h3>
<div class="lb-trans"><h3>Bruker 最近的表現如何？</h3>
</div><p>Bruker certainly has been doing a good job lately as it's been growing revenue more than most other companies. It might be that many expect the strong revenue performance to degrade substantially, which has repressed the share price, and thus the P/S ratio. If not, then existing shareholders have reason to be quite optimistic about the future direction of the share price.</p>
<div class="lb-trans"><p>Bruker 最近確實表現不錯，因為其收入增長超過了大多數其他公司。可能許多人預計強勁的收入表現將大幅下降，這抑制了股價，因此市銷率也隨之下降。如果不是這樣，那麼現有股東對未來股價的方向有理由感到相當樂觀。</p>
</div><p>Keen to find out how analysts think Bruker's future stacks up against the industry? In that case, our <strong>free</strong> report is a great place to start.</p>
<div class="lb-trans"><p>想知道分析師如何看待 Bruker 的未來與行業的比較嗎？那麼，我們的 <strong>免費</strong> 報告是一個很好的起點。</p>
</div><h2>What Are Revenue Growth Metrics Telling Us About The Low P/S?</h2>
<div class="lb-trans"><h2>收入增長指標告訴我們關於低市銷率的什麼？</h2>
</div><p>In order to justify its P/S ratio, Bruker would need to produce anemic growth that's substantially trailing the industry.</p>
<div class="lb-trans"><p>為了證明其市銷率的合理性，Bruker 需要實現顯著低於行業的微弱增長。</p>
</div><p>Taking a look back first, we see that the company managed to grow revenues by a handy 10% last year. Pleasingly, revenue has also lifted 39% in aggregate from three years ago, partly thanks to the last 12 months of growth. Accordingly, shareholders would have definitely welcomed those medium-term rates of revenue growth.</p>
<div class="lb-trans"><p>回顧過去，我們看到公司去年成功實現了 10% 的收入增長。令人欣慰的是，收入在三年前的基礎上總共增長了 39%，部分得益於過去 12 個月的增長。因此，股東們肯定會歡迎這些中期收入增長率。</p>
</div><p>Shifting to the future, estimates from the eleven analysts covering the company suggest revenue should grow by 3.2% per year over the next three years. Meanwhile, the rest of the industry is forecast to expand by 6.8% per year, which is noticeably more attractive.</p>
<div class="lb-trans"><p>展望未來，覆蓋該公司的 11 位分析師的估計顯示，未來三年收入預計將每年增長 3.2%。與此同時，行業的其他部分預計每年將增長 6.8%，這顯然更具吸引力。</p>
</div><p>With this information, we can see why Bruker is trading at a P/S lower than the industry. It seems most investors are expecting to see limited future growth and are only willing to pay a reduced amount for the stock.</p>
<div class="lb-trans"><p>根據這些信息，我們可以看到為什麼 Bruker 的市銷率低於行業。似乎大多數投資者預計未來增長有限，因此只願意為該股票支付較低的價格。</p>
</div><h2>What Does Bruker's P/S Mean For Investors?</h2>
<div class="lb-trans"><h2>Bruker 的市銷率對投資者意味着什麼？</h2>
</div><p>Shares in Bruker have plummeted and its P/S has followed suit. While the price-to-sales ratio shouldn't be the defining factor in whether you buy a stock or not, it's quite a capable barometer of revenue expectations.</p>
<div class="lb-trans"><p>Bruker 的股價暴跌，其市銷率也隨之下降。雖然市銷率不應成為您是否購買股票的決定性因素，但它是收入預期的一個相當有效的晴雨表。</p>
</div><p>We've established that Bruker maintains its low P/S on the weakness of its forecast growth being lower than the wider industry, as expected. Right now shareholders are accepting the low P/S as they concede future revenue probably won't provide any pleasant surprises. Unless these conditions improve, they will continue to form a barrier for the share price around these levels.</p>
<div class="lb-trans"><p>我們已經確定，Bruker 維持其低市銷率是因為其預測增長低於更廣泛的行業，正如預期的那樣。現在，股東們接受低市銷率，因為他們承認未來的收入可能不會帶來任何令人愉快的驚喜。除非這些條件改善，否則它們將繼續在這些水平上形成股價的障礙。</p>
</div><p>Plus, you should also learn about these <strong>3 warning signs we've spotted with Bruker</strong> (including 1 which can't be ignored).</p>
<div class="lb-trans"><p>此外，您還應該瞭解我們發現的 <strong>Bruker 的 3 個警告信號</strong>（其中 1 個是無法忽視的）。</p>
</div><p>If you're <strong>unsure about the strength of Bruker's business</strong>, why not explore our interactive list of stocks with solid business fundamentals for some other companies you may have missed.</p>
<div class="lb-trans"><p>如果您對 Bruker 的業務實力 <strong>不確定</strong>，為什麼不探索我們互動的股票列表，尋找一些您可能錯過的具有良好商業基礎的其他公司呢？</p>
</div>

為什麼布魯克公司（NASDAQ:BRKR）股價暴跌 31% 不應令投資者感到意外